logo-loader
viewOrgenesis

Orgenesis to conduct clinical study of tumor-infiltrating lymphocytes with Israeli public hospital

The study will evaluate Orgenesis’ novel automated cell culturing system, among other technologies

Tumor graphic
Orgenesis, based in Germantown, Maryland, is focused on accelerating the commercialization of transforming the delivery of cell and gene therapies while also lowering costs

Orgenesis Inc (NASDAQ:ORGS) announced an agreement to conduct a medical study of its proprietary POCare technologies with The Edith Wolfson Medical Center, a public hospital in Israel.

The study will evaluate Orgenesis’ novel automated cell culturing system, among other technologies, which is designed to enable faster and safer generation and expansion of tumor-infiltrating lymphocytes (TIL).

The idea is to provide a simplified method for TIL generation and expansion in an automated, controlled system from initial production to final product with minimal human operation, the company said.

READ: Orgenesis launches research collaboration with Madrid hospital to establish point-of-care center

“Partnering with Edith Wolfson Medical Center, an established and well-respected medical institution, to conduct this clinical trial will further validate our cell processing system for TIL generation and expansion,” Orgenesis CEO Vered Caplan said in a statement. “These POCare Technologies are not only highly versatile, but also highly expandable and as a result, could increase our ability to grow various types of cells for a broad range of customer needs.”

The collaboration is part of Orgenesis’ larger goal of developing new approaches to immune-oncology through its CGT Biotech Platform, Caplan said. The company plans to deploy any such solutions across its POCare Network, which consists of a growing number of medical institutions around the world, including a recently announced collaboration with Hospital Infantil Universitario Niño Jesús in Madrid.

“We look forward to collaborating with Orgenesis on this important clinical trial to advance and validate this breakthrough Orgenesis proprietary TILs technology, with the joint goal of reducing manufacturing costs and bringing new, cell and gene therapy products to cancer patients worldwide,” said Ronen Brenner, head of The Edith Wolfson Medical Center’s oncology division.

The Edith Wolfson Medical Center is a public hospital founded in 1980 and located 

Orgenesis, based in Germantown, Maryland, is focused on accelerating the commercialization of transforming the delivery of cell and gene therapies while also lowering costs.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 5.72 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $125.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read